Champions Oncology
CSBR
29 hedge funds and large institutions have $26.5M invested in Champions Oncology in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
1.86% less ownership
Funds ownership: 46.14% → 44.28% (-1.9%)
9% less funds holding
Funds holding: 32 → 29 (-3)
20% less call options, than puts
Call options by funds: $20K | Put options by funds: $25K
43% less capital invested
Capital invested by funds: $46.8M → $26.5M (-$20.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
+$1.79M |
| 2 |
Millennium Management
New York
|
+$31.2K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$31.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.75M |
| 2 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$999K |
| 3 |
E
Ergoteles
New York
|
-$105K |
| 4 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$98.8K |
| 5 |
Renaissance Technologies
New York
|
-$59.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Dimensional Fund Advisors
Austin,
Texas
| $550 | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $189 | +$7 | +1 | +2% |
|
|
E
28
Ergoteles
New York
| – | -$105K | -13,937 | Closed |
|
29
Barclays
London,
United Kingdom
| – | -$10K | -1,342 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$196 | -30 | -17% |
|
CSBR Hedge Fund Activity: Q4 2022 in Review
29 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q4 2022, worth a combined $26.5M — down 43% from $46.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CSBR and 1 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was Tocqueville Asset Management, adding an estimated $1.79M. The largest seller was Vanguard Group, cutting an estimated $1.75M.
- 29 institutional investors held Champions Oncology (CSBR) as of Q4 2022, down from 32 in Q3 2022.
- Funds reported $26.5M of Champions Oncology stock for Q4 2022, down 43% quarter-over-quarter.
- 1 fund opened new Champions Oncology positions in Q4 2022 and 3 closed out, a net change of -2 holders.
- The largest Champions Oncology buyer in Q4 2022 was Tocqueville Asset Management, an estimated $1.79M added.
- The largest Champions Oncology seller in Q4 2022 was Vanguard Group, an estimated $1.75M sold.
Based on aggregated 13F filings for Q4 2022.